Treatment of Falciparum Malaria from Vietnam with a Phenanthrene Methanol (WR 33063) and a Quinoline Methanol (WR 30090) | Zendy

Craig J. Canfield | Zendy; Anthony Hall | Zendy; Bruce S. MacDonald | Zendy; David A. Neuman | Zendy; James A. Shaw | Zendy

Open Access

Treatment of Falciparum Malaria from Vietnam with a Phenanthrene Methanol (WR 33063) and a Quinoline Methanol (WR 30090)

Author(s) -

Craig J. Canfield,

Anthony Hall,

Bruce S. MacDonald,

David A. Neuman,

James A. Shaw

Publication year - 1973

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.3.2.224

Subject(s) - malaria , quinoline , plasmodium falciparum , medicine , drug , chloroquine , mefloquine , pharmacology , phenanthrene , traditional medicine , biology , immunology , chemistry , organic chemistry , astrobiology

Two new investigational antimalarial drugs developed by the U.S. Army Malaria Research Program were tested in patients with multi-drug-resistant falciparum malaria from Vietnam. WR 33063, a phenanthrene methanol, cured 13 patients treated in the United States. All of these patients had suffered multiple recrudescences after treatment with standard antimalarial drugs. In addition, 23 of 25 patients with acute attacks of falciparum malaria treated in Vietnam were cured. The rate of clinical response was prompt. WR 30090, a quinoline methanol, similarly cured eight patients with multiple recrudescences in the United States and 23 of 26 patients in Vietnam. Adverse effects associated with the drugs were not seen. These drugs signify a major advance in the chemotherapy of drug-resistant falciparum malaria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research